» Articles » PMID: 20550527

Morbidity and Mortality in Patients with Craniopharyngioma After Surgery

Overview
Specialty Endocrinology
Date 2010 Jun 17
PMID 20550527
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Craniopharyngioma (CP) is a benign tumour of the suprasellar region that is associated with increased morbidity and mortality in comparison with other causes of hypopituitarism. We aimed to establish the rate and causes of mortality and morbidity in patients with CP who attended our centre.

Design: We performed a retrospective case note audit of patients with CP who were managed by our service. We established the standardized mortality ratio (SMR) for patients with CP. We compared obesity prevalence with two other hypopituitary groups who are managed by our service.

Patients: We identified 70 patients with CP, 97% of whom had undergone surgery and 42% radiotherapy. We compared the prevalence of obesity with that of 89 patients with hypopituitarism secondary to surgery for nonfunctioning pituitary adenoma and 29 patients with post-traumatic hypopituitarism (PTHP).

Measurements: Standardized mortality ratio for patients with CP was 8.75 (95% CI of 5.4-13.3); SMR for women was 10.51 (95% CI 5.04-19.3) and 7.55 (95% CI 3.77-13.52) for men. The rates of growth hormone (GH), gonadotrophin, adrenocorticotrophic hormone (ACTH) and TSH deficiencies were 91%, 93.5%, 92% and 86%, respectively. The rate of diabetes insipidus (DI) was 81%; 7.1% had adipsic DI. Dyslipidaemia was present in 46.9% and diabetes mellitus in 11.5%. Obesity affected 66% of patients with CP, 47% of patients with nonfunctioning adenoma and 31% of those with PTHP (P < 0.001).

Conclusions: Patients with CP suffer from high rates of mortality and morbidity. The underlying causes for mortality and for obesity in this population remain poorly understood.

Citing Articles

Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review.

Cossu G, Ramsay D, Daniel R, El Cadhi A, Kerherve L, Morlaix E Cancers (Basel). 2024; 16(20).

PMID: 39456573 PMC: 11506763. DOI: 10.3390/cancers16203479.


Intraoperative application of low-dose dexmedetomidine or lidocaine for postoperative analgesia in pediatric patients following craniotomy: a randomized double-blind placebo-controlled trial.

Bao D, Wang Y, Xiong W, Zhang D, Qiao L, Zheng N Front Surg. 2024; 11:1371588.

PMID: 38978991 PMC: 11228272. DOI: 10.3389/fsurg.2024.1371588.


Risk-benefit analysis of surgical treatment strategies for cystic craniopharyngioma in children and adolescents.

Schmutzer-Sondergeld M, Quach S, Niedermeyer S, Teske N, Ueberschaer M, Schichor C Front Oncol. 2024; 14:1274705.

PMID: 38292926 PMC: 10825040. DOI: 10.3389/fonc.2024.1274705.


Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma.

Miao Y, Fan K, Peng X, Li S, Chen J, Bai R Front Endocrinol (Lausanne). 2023; 14:1241145.

PMID: 38027203 PMC: 10657986. DOI: 10.3389/fendo.2023.1241145.


Correlations between the expression of molecules in the TGF-β signaling pathway and clinical factors in adamantinomatous craniopharyngiomas.

Jin L, Cai K, Wu W, Xiao Y, Qiao N, Liu F Front Endocrinol (Lausanne). 2023; 14:1167776.

PMID: 37854185 PMC: 10579895. DOI: 10.3389/fendo.2023.1167776.